Applied BioCode Cash Flow Conversion Efficiency

Latest as of September 2025: -0.029x

Applied BioCode cash flow conversion efficiency. Based on the latest financial reports, Applied BioCode (6598) has a cash flow conversion efficiency ratio of -0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-19.88 Million ≈ $-626.20K USD) by net assets (NT$687.57 Million ≈ $21.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Applied BioCode (2013–2024)

Cash flow conversion efficiency of Applied BioCode from 2013 to 2024. This chart illustrates how Applied BioCode's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Applied BioCode stock quote for real-time trading data and today's change.

Applied BioCode Cash Flow Conversion Ratio Explained

Applied BioCode cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Applied BioCode Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Applied BioCode ranked by their cash flow conversion efficiency. Also see 6598 stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Fifth District Bancorp, Inc. Common Stock NASDAQ:FDSB	0.007x
Infant Bacterial Therapeutics AB (publ) ST:IBT-B	-0.420x
Spyrosoft Spólka Akcyjna F:2NP	0.126x
Nanjing Putian Telecommunications Co Ltd Class B SHE:200468	-0.492x
Nabaltec AG F:NTG	-0.054x
DeviceENG.CO.Ltd KQ:187870	0.035x
Western Asset Investment Grade Defined Opportunity Closed Fund NYSE:IGI	N/A
Lanvin Group Holdings Limited NYSE:LANV	0.322x

Annual Cash Flow Conversion Efficiency for Applied BioCode (2013–2024)

The table below shows the annual cash flow conversion efficiency of Applied BioCode from 2013 to 2024. Review Applied BioCode free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$878.83 Million ≈ $27.69 Million	NT$-207.74 Million ≈ $-6.54 Million	-0.236x	+23.82%
2023-12-31	NT$660.99 Million ≈ $20.82 Million	NT$-205.09 Million ≈ $-6.46 Million	-0.310x	-273.58%
2022-12-31	NT$816.07 Million ≈ $25.71 Million	NT$145.87 Million ≈ $4.60 Million	0.179x	+206.34%
2021-12-31	NT$902.96 Million ≈ $28.45 Million	NT$-151.77 Million ≈ $-4.78 Million	-0.168x	-24.51%
2020-12-31	NT$1.09 Billion ≈ $34.25 Million	NT$-146.74 Million ≈ $-4.62 Million	-0.135x	+77.17%
2019-12-31	NT$530.65 Million ≈ $16.72 Million	NT$-313.84 Million ≈ $-9.89 Million	-0.591x	+10.74%
2018-12-31	NT$432.73 Million ≈ $13.63 Million	NT$-286.71 Million ≈ $-9.03 Million	-0.663x	+26.82%
2017-12-31	NT$276.52 Million ≈ $8.71 Million	NT$-250.36 Million ≈ $-7.89 Million	-0.905x	+13.77%
2016-12-31	NT$427.60 Million ≈ $13.47 Million	NT$-448.96 Million ≈ $-14.14 Million	-1.050x	-35.65%
2015-12-31	NT$270.32 Million ≈ $8.52 Million	NT$-209.24 Million ≈ $-6.59 Million	-0.774x	-89.71%
2014-12-31	NT$315.69 Million ≈ $9.95 Million	NT$-128.80 Million ≈ $-4.06 Million	-0.408x	+24.14%
2013-12-31	NT$170.93 Million ≈ $5.39 Million	NT$-91.93 Million ≈ $-2.90 Million	-0.538x	--

About Applied BioCode

TW:6598 Taiwan Medical Devices

Market Cap

$91.98 Million

NT$2.92 Billion TWD

Market Cap Rank

#19332 Global

#1111 in Taiwan

Share Price

NT$28.40

Change (1 day)

-2.41%

52-Week Range

NT$20.55 - NT$31.50

All Time High

NT$177.50